UK invests in $12.5-million Stem-Cell Institute - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

UK invests in $12.5-million Stem-Cell Institute



The UK is to invest £8 million ($12.5 million) in a new center that will be dedicated to stem-cell biology and medicine, with the aim of developing new therapeutic approaches to illnesses that currently have no effective treatments. The funding will come from the UK’s Medical Research Council and the Wellcome Trust, two of the country’s largest funders of medical research.

According to a press statement, stem cells have shown promise in potential treatments for liver disease, diabetes, blindness, spinal cord injury, and neurodegenerative disorders, and can be used to study the mechanisms of human disease. The institute, named The Wellcome Trust–Medical Research Council Cambridge Stem Cell Institute, will bring together research scientists, technology specialists, and doctors, and will principally focus on the areas of pluripotency, haematopoiesis, epithelial tissues, neural, and cardiovascular stem cells.

“Our aim is to close the knowledge gap and to drive stem-cell research towards clinical applications,” Austin Smith, the director of the institute, said in the statement. “The world-class facilities will attract the best international talent from the fields of stem-cell biology and regenerative medicine to pursue this goal.”

An 8000 square meter facility is being purpose-built for the institute on the University of Cambridge’s Biomedical Research Campus. The location, close to one of Europe’s largest biotechnology clusters, will provide ample opportunity for industry collaboration.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here